GHRH receptor agonist, stimulating endogenous pulsatile growth hormone release rather than supplying growth hormone directly.
What was measuredThe pulsatile mechanism is established and is why it was licensed where exogenous growth hormone was not.
Also known as TH9507 · developed by Theratechnologies
Licensed by at least one major regulator for a specific indication, on the strength of completed phase 3 trials. Approval is for that indication in that population — it is not a general endorsement of the compound.
A stabilised analogue of growth hormone releasing hormone, and one of the few growth hormone secretagogues to complete clinical development and reach approval.
GHRH receptor agonist, stimulating endogenous pulsatile growth hormone release from the pituitary rather than supplying growth hormone directly.
Phase 3 trials showed reduction in visceral adipose tissue in people with HIV-associated lipodystrophy, supporting FDA approval in 2010.
Later trials examined liver fat in people with HIV, reporting reductions in hepatic fat fraction.
This is a summary of what has been reported in the literature, not a complete safety profile. For anything concerning your own health, speak to a doctor.
FDA-approved, prescription-only, for a specific HIV-associated indication.
The sites below are where Tesamorelin is understood to act, paired with what was actually measured there and in whom. A site on this diagram means a compound acts there — not that a benefit is established.
Drag to turn · tap an organ
GHRH receptor agonist, stimulating endogenous pulsatile growth hormone release rather than supplying growth hormone directly.
What was measuredThe pulsatile mechanism is established and is why it was licensed where exogenous growth hormone was not.
Reduces visceral adipose tissue.
What was measuredApproved for HIV-associated lipodystrophy on the strength of visceral fat reduction. The licence is for that population, not for general fat loss.
Studied for reduction of liver fat.
What was measuredTrials in NAFLD showed reductions in hepatic fat. Not approved for this indication.
This site publishes summaries of published research. It is not medical advice, and Genexis Health does not sell or supply any compound described here. Please confirm each statement below to continue.
We ask everyone to confirm they understand this site is information rather than medical advice before reading it. Because you have not confirmed those statements, you cannot continue.
If you are looking for health advice or treatment, please speak to a licensed healthcare professional. Nothing on this site is a substitute for that.